A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Inclusion Criteria

• •1. Males and females, \>/= 18 years of age.
• •2. Chronic spontaneous urticaria (CSU) \>/= 6 months prior to Screening (Visit 1).
• •3. CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:
• •1. The presence of hives for \>/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.
• •2. Must be on a stable regimen of second generation non-sedating H1-antihistamine for \>/= 4 weeks prior to study treatment.
• •3. UAS7 of \>/= 16 and ISS7 of \>/= 8 during the 7 days prior to study treatment.
• •4. Normal blood counts and liver function tests.
• •5. Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.
• •6. Willing and able to complete a daily symptom electronic diary and comply with study visits.
• •7. Participants with and without prior biologic experience are eligible.